Clinical Trials Logo

Clinical Trial Details — Status: Unknown status

Administrative data

NCT number NCT02002676
Other study ID # 2013KLY-022
Secondary ID
Status Unknown status
Phase N/A
First received November 26, 2013
Last updated June 12, 2014
Start date December 2013
Est. completion date June 2014

Study information

Verified date June 2014
Source Nanjing University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients in critical illness frequently present hypermetabolism, which can extremely increase the rest energy expenditure(REE). We hypothesize that if we alleviate the extremely increased REE will improve ICU patients' outcome


Description:

This study focuses on the early changes of REE of critical ill patients when they admitted to ICU.


Recruitment information / eligibility

Status Unknown status
Enrollment 62
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Older than 18 year.

- APACHE? score=8

Exclusion Criteria:

- Hypercortisolism

- Thyroid disease

- Tracheoesophageal fistula

- FiO2>60 or PEEP>12cm H2O in mechanical ventilate

- Pregnancy

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Nanjing University School of Medicine Nanjing Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Nanjing University School of Medicine Jinling Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Length of stay in ICU Length of ICU stay within 60 days
Primary Mortality rate of 28 days From ICU admission to 28th days of observation
Secondary Incidence of Multiple Organ Dysfunction Syndrome(MODS)in 60 days From ICU admission to 60th days of observation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3